Literature DB >> 16275340

Purification, crystallization, and X-ray analysis of the yeast 20S proteasome.

Michael Groll1, Robert Huber.   

Abstract

Intracellular protein degradation is one of the most precisely regulated processes in living cells. The main component of the degradation machinery is the 20S proteasome present in eukaryotes as well as in prokaryotes. We have developed successful purification protocols for the 20S proteasome in its native state using an affinity tag strategy. This chapter describes in detail the purification protocols, proteolytic activity assays, crystallization, and structure determination for the yeast 20S proteasome. The crystal structure of the eukaryotic proteasome opens new possibilities for identifying, characterizing, and elucidating the mode of action for natural and synthetic inhibitors, which affect its function. Some of these compounds may find therapeutic applications in contemporary medicine.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16275340     DOI: 10.1016/S0076-6879(05)98027-0

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  18 in total

1.  α,β-Unsaturated carbonyl system of chalcone-based derivatives is responsible for broad inhibition of proteasomal activity and preferential killing of human papilloma virus (HPV) positive cervical cancer cells.

Authors:  Martina Bazzaro; Ravi K Anchoori; Mohana Krishna R Mudiam; Olga Issaenko; Srinivas Kumar; Balasubramanyam Karanam; Zhenhua Lin; Rachel Isaksson Vogel; Riccardo Gavioli; Federica Destro; Valeria Ferretti; Richard B S Roden; Saeed R Khan
Journal:  J Med Chem       Date:  2010-12-27       Impact factor: 7.446

2.  Inhibitor-binding mode of homobelactosin C to proteasomes: new insights into class I MHC ligand generation.

Authors:  Michael Groll; Oleg V Larionov; Robert Huber; Armin de Meijere
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-13       Impact factor: 11.205

3.  Synthetic and structural studies on syringolin A and B reveal critical determinants of selectivity and potency of proteasome inhibition.

Authors:  Jérôme Clerc; Michael Groll; Damir J Illich; André S Bachmann; Robert Huber; Barbara Schellenberg; Robert Dudler; Markus Kaiser
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-09       Impact factor: 11.205

4.  Proteasome inhibition by fellutamide B induces nerve growth factor synthesis.

Authors:  John Hines; Michael Groll; Margaret Fahnestock; Craig M Crews
Journal:  Chem Biol       Date:  2008-05

5.  A humanized yeast proteasome identifies unique binding modes of inhibitors for the immunosubunit β5i.

Authors:  Eva M Huber; Wolfgang Heinemeyer; Gerjan de Bruin; Herman S Overkleeft; Michael Groll
Journal:  EMBO J       Date:  2016-10-27       Impact factor: 11.598

6.  Membrane proteases and aminoglycoside antibiotic resistance.

Authors:  Aaron Hinz; Samuel Lee; Kyle Jacoby; Colin Manoil
Journal:  J Bacteriol       Date:  2011-07-15       Impact factor: 3.490

7.  Enzyme inhibition by hydroamination: design and mechanism of a hybrid carmaphycin-syringolin enone proteasome inhibitor.

Authors:  Daniela B B Trivella; Alban R Pereira; Martin L Stein; Yusuke Kasai; Tara Byrum; Frederick A Valeriote; Dean J Tantillo; Michael Groll; William H Gerwick; Bradley S Moore
Journal:  Chem Biol       Date:  2014-06-12

8.  Design, synthesis, and evaluation of cystargolide-based β-lactones as potent proteasome inhibitors.

Authors:  Doleshwar Niroula; Liam P Hallada; Camille Le Chapelain; Susantha K Ganegamage; Devon Dotson; Snezna Rogelj; Michael Groll; Rodolfo Tello-Aburto
Journal:  Eur J Med Chem       Date:  2018-08-20       Impact factor: 6.514

9.  Quinone reductase acts as a redox switch of the 20S yeast proteasome.

Authors:  Sonja Sollner; Markus Schober; Andrea Wagner; Anna Prem; Lucie Lorkova; Bruce A Palfey; Michael Groll; Peter Macheroux
Journal:  EMBO Rep       Date:  2008-11-21       Impact factor: 8.807

10.  Phylogeny-guided interaction mapping in seven eukaryotes.

Authors:  Janusz Dutkowski; Jerzy Tiuryn
Journal:  BMC Bioinformatics       Date:  2009-11-30       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.